NCT05193227View on ClinicalTrials.gov

Sustained Release Lidocaine for the Treatment of Postoperative Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

April 27, 2026

Study Completion Date

May 27, 2026

Conditions
Postoperative PainPostsurgical Pain
Interventions
DRUG

ST-01

Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)

DRUG

Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)

Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)

Trial Locations (2)

V5Z 1M9

RECRUITING

Vancouver Prostate Centre, Vancouver

V7Z1Y6

RECRUITING

St. Pauls Hospital, Vancouver

All Listed Sponsors
collaborator

Sustained Therapeutics Inc.

INDUSTRY

lead

University of British Columbia

OTHER